# Endoscopic Ultrasound Radiofrequency Ablation and Immunotherapy Pembrolizumab for Locally Advanced Unresectable and Metastatic Pancreatic Duct Adenocarcinoma

Source: https://onco.cc/trials/nct06831136/  
OnCo record `nct06831136` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial in pancreatic cancer, run by The University of Texas Health Science Center, Houston, now recruiting.

## Summary

Endoscopic Ultrasound Radiofrequency Ablation and Immunotherapy Pembrolizumab for Locally Advanced Unresectable and Metastatic Pancreatic Duct Adenocarcinoma is a phase 2, interventional study registered as NCT06831136 by The University of Texas Health Science Center, Houston, with a registry enrolment figure of 24 participants, started 2025-03-26 and due to reach its primary completion in 2028-01-20. Interventions recorded: Neoadjuvant Chemotherapy (NAC); Immunotherapy (pembrolizumab); Endoscopic ultrasound (EUS)-guided radiofrequency ablation (RFA). Conditions listed: Pancreatic Ductal Adenocarcinoma. Primary outcome: Efficacy as assessed by the Overall response rate using RECIST v1.1 guidelines. Pancreatic eligibility wording from the registry: "Patients who have undergone prior resection will be excluded unless there is recurrent pancreatic tumor that is amenable to EUS-RFA". Sites: United States. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-24
- Also known as: PANCARDINAL-2
- Tags: ctgov-ingest; pancreatic-deep-dive
- Registry id: NCT06831136
- Phase: 2
- Setting: Endoscopic Ultrasound Radiofrequency Ablation and Immunotherapy Pembrolizumab for Locally Advanced Unresectable and Metastatic Pancreatic Duct Adenocarcinoma; a Phase II Trial PANcreas CAncer RaDIofrequeNcy AbLation
- Sponsor: The University of Texas Health Science Center, Houston
- Enrolled: 24

## Sources

- ClinicalTrials.gov NCT06831136: https://clinicaltrials.gov/study/NCT06831136

## Connected records

- cancers: [Locally advanced unresectable pancreatic ductal adenocarcinoma](https://onco.cc/cancers/locally-advanced-pdac/), [Metastatic pancreatic ductal adenocarcinoma](https://onco.cc/cancers/metastatic-pdac/)
- terms: [Pancreatic cancer trials open today (registry snapshot and UK sites)](https://onco.cc/terms/pancreatic-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct06831136.json